Johnson & Johnson Secures FDA Approval for TECVAYLI plus DARZALEX FASPRO Combination Therapy in Multiple Myeloma

Johnson & Johnson has announced the U.S. Food and Drug Administration’s (FDA) approval of TECVAYLI (teclistamab) in combination with DARZALEX FASPRO (daratumumab hyaluronidase-fihj) for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. This approval is based on data from the phase 3 CASTOR-2 trial, which demonstrated a median progression-free survival of 24.6 months in the combination arm compared to 11.3 months in the control group. The regimen has shown a confirmed overall response rate of 78.9% among patients with high-risk cytogenetics, a population historically difficult to treat. The approval positions JNJ as a leader in dual-targeting immunotherapies for hematologic malignancies, leveraging bispecific antibodies and monoclonal antibodies in a single treatment strategy. TECVAYLI, a B-cell maturation antigen (BCMA)-directed bispecific antibody, and DARZALEX FASPRO, a CD38-targeted monoclonal antibody, are designed to enhance immune system engagement and tumor cell lysis. The combination is administered subcutaneously, offering a streamlined dosing regimen that may improve patient adherence and clinic efficiency. This regulatory milestone is expected to contribute meaningfully to JNJ’s oncology segment, which contributed approximately $13.4 billion in revenue during 2024. Analysts project the combination therapy could capture a significant share of the $15 billion global multiple myeloma market over the next five years, particularly in high-risk patient populations. The approval also supports the broader healthcare sector, with related ETFs such as XLV and IHF likely to see upward momentum due to investor confidence in JNJ’s pipeline and commercial execution.